Abstract:Hyperprolactinemia is commonly found in both female and male patients with abnormal sexual and/or reproductive function or with galactorrhea. If serum prolactin levels are above 200 microg/L, a prolactin-secreting pituitary adenoma (prolactinoma) is the underlying cause, but if levels are lower, differential diagnoses include the intake of various drugs, compression of the pituitary stalk by other pathology, hypothyroidism, renal failure, cirrhosis, chest wall lesions, or idiopathic hyperprolactinemia. When a pituitary tumor is present, patients often have pressure symptoms in addition to endocrine dysfunction, such as headaches, visual field defects, or cranial nerve deficits. The large majority of patients with prolactinomas, both micro- and macroprolactinomas, can be successfully treated with dopaminergic drugs as first-line treatment, with normalization of prolactin secretion and gonadal function, and with significant tumor shrinkage in a high percentage of cases. Surgical resection of the prolactinoma is the option for patients who may refuse or do not respond to long-term pharmacological therapy. Radiotherapy and/or estrogens are also reasonable choices if surgery fails. In patients with asymptomatic microprolactinoma no treatment needs to be given and a regular follow-up with serial prolactin measurements and pituitary imaging should be organized. Currently, the most commonly used dopamine agonists are bromocriptine, pergolide, quinagolide and cabergoline. When comparing the plasma half-life, efficacy and tolerability of these drugs, cabergoline seems to have the most favorable profile, followed by quinagolide. Ifprolactin levels are well controlled with dopamine agonist therapy, gradual tapering of the dose to the lowest effective amount is recommended, and in a number of cases medication can be stopped after several years. Evidence to date suggests that cabergoline and quinagolide appear to have a good safety profile for women who wish to conceive, but hard evidence proving that dopamine agonists do not provoke congenital malformations when taken during early pregnancy is currently only available for bromocriptine. Once pregnant, dopamine agonist therapy should be immediately stopped, unless growth of a macroprolactinoma is likely or pressure symptoms occur. At our institution patients with symptomatic prolactinomas, both micro- and macroadenomas, are treated with cabergoline as the first-line aproach. In the small group of patients who do not respond to this treatment, or who refuse long-term therapy, surgery is offered. Radiotherapy is given if both pharmacologic therapy and surgery fail.

Prolactinoma and hyperprolactinaemia: a transcultural comparative study between Germany as a western, liberal, industrialised country and Syria as an oriental society with a strong Islamic tradition

Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses

Demographic characteristics, presentations and treatment outcome of patients with prolactinoma

Hyperprolactinaemia: analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital

Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years

Hyperprolactinemia and hypogonadism in the human female

The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia

"Real-world" pediatric endocrine practice; how much is it influenced by physician's gender and region of practice. Results of an international survey

Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance

[What to do when faced with hyperprolactinemia?]

Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine

(405) Gonadis National Registry On Gonadal Status In Pituitary And Adrenal Disorders: Prevalence And Characterization Of Sexual Dysfunctions In Male Patients With Hyperprolactinemia

Hyperprolactinemia in children: clinical features and long-term results

Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism

Effect of hyperprolactinemia upon clinical symptoms of patients with polycystic ovary syndrome]

Hyperprolactinemia: pathophysiology and management

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women

Treatment of hyperprolactinemia: a systematic review and meta-analysis

Metabolic Abnormalities, Inflammatory Markers and Endothelial Dysfunction in Hyperprolactinemia due to Prolactinoma before and after Normalization of Serum Prolactin: A Prospective Case Control Study

Management of prolactinomas in Brazil: an electronic survey